The Dolcera Blog

This is in continuation to my previous post on Patenting Landscape in India which could be read from the link given below
http://blogs.dolcera.com/blog/2009/07/18/patenting-landscape-in-india-a-view-on-patenting-trends-in-india-a-dolcera-analysis/

In this post the Analysis concentrates on finding the Top companies who have maximum publication in the Indian Patent Office. The Top Companies were searched for the patents published between 01st January 2005 -21st July 2009. The patents filed in all the 4 Indian Patent offices are considered

The Top 15 Companies

From the Graph one can conclude that Qualcomm leads in the race for Publications in the Indian Patent Office with 2118 publications followed by Philips Electronics and Council of Scientific and Industrial Research. Qualcomm deals with electronics and communication products. Since India is a major market for Mobile/ Cell phone, Qualcomm has a good advantage for its patents filed in India to get protection for its inventions

The Top Indian Assignees

From the Graph one can see that Council of Scientific and Industrial Research(CSIR) is the Top Indian Assignee when it comes to publications in India with 1541 publications followed by Hindustan Unilever Ltd. with 523 publications. But CSIR still trails with Qualcomm and hence it is necessary to encourage more research to be the Top patent filer in India.

Of the Top 100 Companies that Dolcera has analysed, 8 Indian companies happen to be in it while the rest of them are Foreign companies. It means 92 % of the Top publications in India are by MNCs. This scenario should be looked upon since the domestic Patent filers in other countries like the US, Japan, China are neck to neck with the International Filers. This should be seriously be looked upon by Indian Companies since it shows that most Indian companies concentrate/Invest only a small part of their budget to R&D activities. The Indian Government should also encourage Indian Universities to carry out R&D activities so that India could become a recognized country in R&D developments.

-Anil Sharma

Knowledge Scientist

Dolcera

© Dolcera 2009, All Rights Reserved. No part of this publication should be copied without the permission from the authour or from Dolcera.

Disclaimer:  There can be manual errors and the author or the company(Dolcera) takes no responsibility for the damage caused due to the data provided.

Tweet  Delicious  Digg  Facebook 

Mumbai, May 18 The Council of Scientific and Industrial Research (CSIR) has received a United States patent on an innovative process to make sevelamer, a generic polymer that treats toxic excess of phosphate in the body caused by chronic renal failure.

The patent is a culmination of work done by CSIR’s constituent lab in Pune, the National Chemical Laboratory, on a mandate initially given by Mumbai-based drug company USV Ltd.

USV had acquired the patent rights from CSIR last year, following which it further undertook the prosecution of the application.

Dr Kulkarni’s team developed the alternative process that received the patent.

As per the agreement, USV had the first right to license the know-how and acquire the patent rights, and USV exercised this option.

USV had approached NCL in mid-2003 to develop an innovative process to manufacture the polymer. NCL developed the process and CSIR filed the patent application in India, and the US.

NCL’s scientists developed a cost-effective process to manufacture sevelamer, the phosphate-absorbing polymer. The process NCL reduces the manufacturing time and the process chemicals requirements and is easy to scale up. USV has made a one time payment, and no further milestone payments are involved, he said, citing confidentiality for not giving details.

This development is significant as a technologically novel process received a US patent and has been found commercially attractive by a pharma company.

The recent patent success comes against the backdrop of the Centre’s efforts to get more public-funded institutions to file patents and work with the industry to commercialise research efforts.

With 128 patents in 2006-2007, the CSIR accounts for about 47 per cent of the total US patents granted to Indians, excluding non-resident Indians and foreign assignees, said Mr R.K. Gupta, Head of CSIR’s IP Management Division.

Final patent

The final patent on the CSIR-developed innovative polymer will be issued by the US Patent Office in approximately four months, said Pharmaceutical Patent Attorneys, LLC, the New Jersey-based firm who prosecuted the patent for its Indian client.

Tweet  Delicious  Digg  Facebook